The effect of sub-antimicrobial dose-doxycycline periodontal therapy on serum inflammatory biomarker C-reactive protein levels in post-menopausal Women: A 2-year, double-blinded, randomized clinical trial

Koppikar, Rajesh; Agrawal, Sneh

doi:10.4103/0976-237x.111628

Cited by 5 publications

(6 citation statements)

References 15 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, Group two showed significant decrease in CRP level which seems parallel with other studies investigated that sub antimicrobial doses of doxycycline could significantly reduce serum CRP and serum IL-6 levels in patients with coronary artery disease and in postmenopausal women with chronic periodontitis [35].…”

Section: Discussionsupporting

confidence: 72%

Role of Commiphora Mol Mol and Doxycycline in Prophylaxis of Spontaneous Bacterial Peritonitis in Egyptians Cirrhotic Patients

Mostafa¹,

Ibrahim²,

Badra³

et al. 2015

Am. J. Biomed. Sci.

View full text Add to dashboard Cite

Aims: this study aimed to evaluate the role of commiphora mol mol and doxycycline in the prophylaxis of spontaneous bacterial peritonitis in cirrhotic patients. Methodology: sixty ascetic cirrhotic patients f r o m National Liver Institute, Menofiya University (Shebeen El-Kom-Egypt) with a history of at least one previous episode of SBP were included in blinded randomized clinical study. Patients were divided into four groups in a fashion; each group consists of 15 patients. Group one received ciprofloxacin (control group), group two received doxycycline, group three received commiphora mol mol and group four received a combination of commiphora mol mol and doxycycline for six months. Serum interleukin 6 (IL 6) and C Reactive Protein (CRP) level were the primary inflammatory markers of the study to evaluate the effect of the studied medications. Results: both IL-6 and CRP levels showed significant decrease three and six months after treatment in all studied groups (P<0.05). Group four showed a significant decrease in IL 6 and CRP level compared with other three groups (P<0.05). Conclusion: the results of the current study strongly support the efficacy of doxycycline and Commiphora molmol as a primary prophylactic therapy in patients with SBP. Furthermore, commiphora mol mol/doxycycline combination was the most effective and showed synergistic effect which may be useful in decrease emergence of resistant strains.

show abstract

Section: Discussionsupporting

confidence: 72%

Role of Commiphora Mol Mol and Doxycycline in Prophylaxis of Spontaneous Bacterial Peritonitis in Egyptians Cirrhotic Patients

Mostafa¹,

Ibrahim²,

Badra³

et al. 2015

Am. J. Biomed. Sci.

View full text Add to dashboard Cite

show abstract

“…SDD as an adjunct to conventional periodontal treatment significantly improves HbA1c levels in diabetic subjects on stable medication, when compared with periodontal treatment alone [ 28 ]. This is a relevant finding in a population using prescribed medication for DM; thus SDD further improves oxidative stress via host-modulatory mechanisms [ 22 , 23 ].…”

Section: Discussionmentioning

confidence: 99%

“…It is an effective free radical scavenger and anti-inflammatory agent [ 21 ]. Systemic SDD as an adjunct to periodontal treatment results in a significant reduction in serum biomarkers of inflammation [ 22 ] including CRP [ 23 ]. In view of the significance of IL-6 and CRP in chronic inflammatory diseases and the anti-inflammatory role of doxycycline, it is relevant to study the effects of these agents alone and in combination in a cell culture model of human osteoblasts, using DHT as a marker of inflammation and oxidative stress; using a novel metabolically active system which would be closer to in vivo conditions.…”

Section: Introductionmentioning

confidence: 99%

Antioxidant Response of Osteoblasts to Doxycycline in an Inflammatory Model Induced by C-reactive Protein and Interleukin-6

Tilakaratne¹,

Soory

2014

IDDT

View full text Add to dashboard Cite

Objectives: Investigation of osteoblastic responses to oxidative stress, induced by C-reactive protein (CRP) and IL-6 and ameliorating effects of doxycycline (Dox); using assays for 5-alpha dihydrotestosterone (DHT) as an antioxidant marker of healing. IL-6 and CRP are risk markers of periodontitis and prevalent comorbidities in periodontitis subjects. Methods: Confluent monolayer cultures of osteoblasts were incubated with radiolabelled testosterone (14C-T) as substrate, in the presence or absence (Control) of pre-determined optimal concentrations of CRP, IL-6, Dox; alone and in combination (n=8) for 24h in MEM. The eluent was solvent-extracted for steroid metabolites. They were separated using TLC in a benzene/ acetone solvent system 4:1 v/v; and quantified using radioisotope scanning. The identity of formed metabolites was confirmed using the mobility of cold standards added to the samples and disclosed in iodine. Further confirmation of the authenticity of DHT was carried out by combined gas chromatrography-mass spectrometry, after derivatization to pentafluorobenzyloxime trimethyl silyl ether. Results: The yields of DHT from 14C-testosterone showed 2-fold and 1.8-fold- inhibition in response to IL-6 and CRP respectively and 28% stimulation in response to Dox, via the 5-alpha reductase pathway. The combination of IL-6 + CRP showed a 2-fold reduction in the yields of DHT, elevated to control values when combined with Dox (n=8; p<0.001). Yields of 4-androstenedione showed an inverse relationship to those of DHT, in response to the agents tested, in keeping with the 17-beta hydroxysteroid dehydrogenase pathway. Conclusions: Inhibition of DHT synthesis in osteoblasts by IL-6 and CRP was overcome by doxycycline. Oxidative actions of IL-6 and CRP; and antioxidant actions of Dox are reinforced by the metabolic yields of DHT in response to agents tested. Using a novel metabolically active model allows closer extrapolation to in vivo conditions; in the context of adjunctive therapeutic applications for periodontitis and prevalent comorbidities.

show abstract

“…Based on the fact that doxycycline 40 mg modified-release inhibits MMP activity, this agent could potentially also be beneficial in the prevention or reduction of CVD risk, as doxycycline has previously been shown to: defend capillary wall and connective tissue integrity; reduce hypersensitivity to vasodilatory stimuli; prevent leakage of capillaries: and inhibit cytokines involved in inflammation [ 92 ]. Furthermore, it has been observed that sub-antimicrobial-dose doxycycline (20 mg twice daily) lowers the levels of the inflammatory biomarker serum C-reactive protein (CRP), with elevated CRP levels being a known CVD risk factor [ 93 ]. By inhibiting the production and activity of MMPs, doxycycline 40 mg modified-release blocks multiple inflammatory pathways, which inhibits the production of proteins contributing to the pathophysiology of PPR inflammation.…”

Section: Treatment Of Inflammatory Lesions Of Rosaceamentioning

confidence: 99%

Topical Ivermectin 10 mg/g and Oral Doxycycline 40 mg Modified-Release: Current Evidence on the Complementary Use of Anti-Inflammatory Rosacea Treatments

et al. 2016

View full text Add to dashboard Cite

Rosacea is a common, chronic inflammatory skin disease that can present with a variety of signs and symptoms. The potentially simultaneous occurrence of different signs and symptoms is due to different underlying inflammatory pathways, emphasizing the need for complementary treatment approaches. Topical ivermectin cream (10 mg/g) and systemic, oral anti-inflammatory doxycycline (40 mg modified-release) are both approved for the treatment of papulopustular rosacea (PPR). Whether or not a combined therapeutic approach may be more beneficial than monotherapy for patients with PPR remains to be tested. Here, we summarize underlying inflammatory pathways implicated in rosacea and clarify the impact of these two agents on selective pathways during inflammation, due to specific characteristics of their individual mechanisms of action (MoA). Based on the complementary MoA of doxycycline modified-release and ivermectin, a scientific rationale for a combined therapy targeting inflammatory lesions in rosacea is given. We propose that topical ivermectin cream is a promising new candidate as first-line treatment to target the inflammatory lesions of rosacea, which can be used in combination with systemic doxycycline modified-release to provide an optimal treatment approach considering all inflammatory pathways involved in PPR.Funding Galderma.

show abstract

The effect of sub-antimicrobial dose-doxycycline periodontal therapy on serum inflammatory biomarker C-reactive protein levels in post-menopausal Women: A 2-year, double-blinded, randomized clinical trial

Cited by 5 publications

References 15 publications

Role of Commiphora Mol Mol and Doxycycline in Prophylaxis of Spontaneous Bacterial Peritonitis in Egyptians Cirrhotic Patients

Role of Commiphora Mol Mol and Doxycycline in Prophylaxis of Spontaneous Bacterial Peritonitis in Egyptians Cirrhotic Patients

Antioxidant Response of Osteoblasts to Doxycycline in an Inflammatory Model Induced by C-reactive Protein and Interleukin-6

Topical Ivermectin 10 mg/g and Oral Doxycycline 40 mg Modified-Release: Current Evidence on the Complementary Use of Anti-Inflammatory Rosacea Treatments

Contact Info

Product

Resources

About